Holen Sie sich die Stockscreener-App
2.91
11.49%
0.30
Handel nachbörslich:
2.92
0.010
+0.34%
Okyo Pharma Limited Aktie (OKYO) Neueste Nachrichten
OKYO Pharma (NASDAQ:OKYO) Shares Down 13.7% – Should You Sell? - Defense World
OKYO Pharma Limited's (NASDAQ:OKYO) market cap rose US$31m last week; individual investors who hold 58% profited and so did insiders - simplywall.st
OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders - Yahoo Finance
OKYO Pharma To Showcase Urcosimod Development At BIO International Convention Next Week - RTTNews
OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts - Proactive Investors
Small cap wrap: Alvopetro, EnWave, OKYO Pharma... - Proactive financial news
Market movers: Chewy, Victoria's Secret, Lockheed Martin, OKYO Pharma... - Proactive financial news
Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited - ACCESS Newswire
Goldman Research Boosts OKYO Pharma Target 60% as Eye Drug Trial Ends Early: Key Catalyst Ahead - Stock Titan
OKYO Pharma CEO to Present Urcosimod Development at Bio International Convention - TipRanks
OKYO Pharma to Present at the Bio International Convention - GlobeNewswire
OKYO Pharma CEO to Present Urcosimod Development for Neuropathic Corneal Pain at Bio International Convention 2025 - Nasdaq
First Treatment for Neuropathic Corneal Pain? OKYO Pharma Reveals Clinical Progress at BIO 2025 - Stock Titan
OKYO Pharma announces presentation at BIO International Convention - Proactive financial news
OKYO Pharma (NASDAQ:OKYO) Stock Price Up 0.5% – Should You Buy? - Defense World
OKYO Pharma stock soars to 52-week high of $1.75 - Investing.com Australia
OKYO Pharma stock soars to 52-week high of $1.75 By Investing.com - Investing.com India
OKYO Pharma has dry eyes as a lucrative prize in its sights - Proactive Investors
OKYO Pharma CEO to Present at Boston Drug Discovery Summit - TipRanks
OKYO Pharma Limited CEO to Present on Urcosimod Development for Neuropathic Corneal Pain at GPCRs-Targeted Drug Discovery Summit - Nasdaq
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit - GlobeNewswire
OKYO Pharma Advances First-Ever Treatment for Neuropathic Corneal Pain at Major Drug Summit - Stock Titan
OKYO Pharma CEO to present drug research for debilitating eye pain at Boston summit - Proactive financial news
OKYO Pharma ("OKYO" or the "Company")announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain - Barchart.com
OKYO Pharma’s (OKYO) Buy Rating Reaffirmed at HC Wainwright - Defense World
Neuropathic Ocular Pain Market Expected to Experience Major - openPR.com
Neuropathic Ocular Pain Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum - Barchart.com
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
OKYO Pharma Limited (NASDAQ:OKYO) Sees Significant Decrease in Short Interest - Defense World
ADS Program collapse - Investegate
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain - marketscreener.com
OKYO moves toward FDA talks after eye drug trial – ICYMI - Proactive financial news
FDA grants fast track to OKYO Pharma’s neuropathic pain drug - Investing.com Australia
Small cap wrap: GoviEx, NextSource Materials, Voyageur Pharmaceuticals, OKYO Pharma... - Proactive financial news
FDA grants fast track to OKYO Pharma’s neuropathic pain drug By Investing.com - Investing.com Nigeria
FDA grants fast track designation to OKYO Pharma’s urcosimod for treatment of neuropathic corneal pain - Ophthalmology Times
OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain - TipRanks
FDA Fast-Tracks Novel Eye Pain Drug: OKYO's Urcosimod Targets Untreated Corneal Condition - Stock Titan
OKYO Pharma secures FDA fast-track designation for urcosimod for neuropathic corneal pain - Proactive financial news
OKYO Pharma accelerates neuropathic corneal pain treatment with early closure of Phase 2 trial - Proactive financial news
Market movers: Snap, Super Micro Computer, OKYO Pharma... - Proactive financial news
Okyo Pharma announces plans to accelerate development of urcosimod - TipRanks
OKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal Pain - TipRanks
OKYO Pharma speeds up NCP drug development - Investing.com
OKYO Pharma Announces Plans to Accelerate the Clinical - GlobeNewswire
OKYO Pharma Limited Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain - marketscreener.com
OKYO Pharma accelerates clinical development of urcosimod for neuropathic corneal pain - Proactive financial news
Press Release Distribution & PR Platform - ACCESS Newswire
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain - ADVFN
OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain - ADVFN
Kyverna Therapeutics (NASDAQ:KYTX) and OKYO Pharma (NASDAQ:OKYO) Financial Review - Defense World
OKYO Pharma CEO discusses FDA Fast Track filing for urcosimodICYMI - Proactive financial news
OKYO Pharma achieves key stability milestone for Urcosimod in clinical development - Proactive financial news
OKYO Stock Price and Chart — NASDAQ:OKYO - TradingView
OKYO Pharma Announces Positive Data in Long-Term Stability of Urcosimod - GlobeNewswire
Small cap wrap: OKYO Pharma, Charbone Hydrogen, Hillcrest... - Proactive financial news
OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment - Seeking Alpha
OKYO Pharma releases positive long-term stability data for urcosimod in neuropathic corneal pain - Ophthalmology Times
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):